The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

How Memorial Hermann Uses an Evidence Aggregation Platform

Posted by Jim Davis on December 8, 2016

Healthcare systems are generally slow to adopt new technologies. For all the talk about leveraging “Big Data,” the industry has been even slower to adopt analytics to make those data actionable. In fact, not one state Medicaid agency currently uses an evidence aggregation platform with post-approval adverse drug events intelligence when creating preferred drug lists, writing prior authorization criteria, negotiating supplemental rebates, educating prescribers and dispensers, or performing prospective, concurrent, or retrospective drug utilization reviews. This is in spite of the fact that millions of patient lives are put at risk and billions of dollars are spent every year from adverse drug events. Yet there is no mandate to use readily available, reliable data to inform making decisions about prescription medicines.

Fortunately there are the outliers - innovators and early adopters that see things differently. They know that they can make a difference by incorporating new ideas and approaches to improve patient outcomes and their own bottom lines.

Read More

Topics: RxCost, Evidex, memorial hermann, real world data, hospitals, evidence aggregation platform, cost of drug adverse events, IDN, health system, clinical trial results, adverse events

Use Clinical Trial Results Linked to Real World Data for Better Formulary Reviews

Posted by Jim Davis on November 17, 2016


Managed Care Organizations are reviewing drugs well before a product is approved. According to a survey conducted by Dymaxium (the company behind the AMCP eDossier System) and presented in a recent webinar, two out of three healthcare decision makers begin to evaluate a drug at least six months prior to approval. The survey also indicates that the primary source of information that payers are using for these pre-approval evaluations is clinicaltrials.gov (CT.gov), and that manufacturers are not always responsive to requests for information pre-approval.

Read More

Topics: Formulary, Drug Formulary, Evidex, real world data, evidence aggregation platform, clinical trial results, adverse events

Establish Drug Safety Benchmarks with an Evidence Aggregation Platform

Posted by Jim Davis on October 27, 2016

 


Drug safety is often equated with post-marketing pharmacovigilance, something that is required by manufacturers only after their drug is approved. But when drug safety data are presented in an evidence aggregation platform there are very strong use cases in pharmaceutical competitive intelligence, health economics and outcomes (HEOR), and R&D. An evidence aggregation platform takes multiple sources of information and boils it down into actionable insight. That insight often has use cases that span all departments and can meet the demands of various priorities. 

Read More

Topics: Drug Safety, Evidex, benchmarks, real world data, evidence aggregation platform, clinical trial results, adverse events

How HEOR Can Demonstrate Cost Burden of Drug Adverse Events

Posted by Jim Davis on October 6, 2016

 


Health Economics and Outcomes Research (HEOR) teams are using evidence aggregation platforms to conduct observational and retrospective studies using both clinical trial results and real world data. Whether a single database is being used for analysis or a combination of multiple datasets are combined, the best evidence aggregation platforms will incorporate standardized analytics that allow for efficient and effective insight generation. One of the key resources a HEOR team needs is the ability to standardize the downstream medical costs of drug adverse events.

Read More

Topics: RxCost, Evidex, HEOR, real world data, evidence aggregation platform, cost of drug adverse events, clinical trial results, adverse events

Subscribe to Email Updates